Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 20 studies | 44% ± 17% | |
lung | 19 studies | 53% ± 18% | |
brain | 18 studies | 41% ± 16% | |
intestine | 12 studies | 53% ± 23% | |
eye | 10 studies | 53% ± 20% | |
kidney | 9 studies | 53% ± 14% | |
liver | 7 studies | 45% ± 22% | |
bone marrow | 6 studies | 35% ± 20% | |
lymph node | 6 studies | 57% ± 16% | |
heart | 6 studies | 25% ± 9% | |
pancreas | 5 studies | 66% ± 22% | |
uterus | 5 studies | 68% ± 16% | |
prostate | 5 studies | 54% ± 23% | |
placenta | 4 studies | 47% ± 16% | |
adipose | 4 studies | 39% ± 17% | |
esophagus | 4 studies | 50% ± 28% | |
breast | 4 studies | 61% ± 8% | |
adrenal gland | 3 studies | 50% ± 10% | |
skin | 3 studies | 56% ± 9% | |
thymus | 3 studies | 63% ± 20% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 39589.59 | 180 / 180 | 100% | 250.09 | 430 / 430 |
prostate | 100% | 22091.98 | 245 / 245 | 100% | 235.91 | 502 / 502 |
brain | 100% | 31792.43 | 2639 / 2642 | 100% | 216.03 | 705 / 705 |
lung | 100% | 21103.48 | 578 / 578 | 100% | 216.50 | 1153 / 1155 |
uterus | 100% | 28612.29 | 170 / 170 | 100% | 230.64 | 457 / 459 |
breast | 100% | 22360.75 | 459 / 459 | 100% | 191.28 | 1113 / 1118 |
thymus | 100% | 23115.20 | 653 / 653 | 100% | 311.16 | 602 / 605 |
esophagus | 100% | 22354.25 | 1445 / 1445 | 99% | 176.34 | 182 / 183 |
intestine | 100% | 26237.67 | 966 / 966 | 99% | 171.46 | 524 / 527 |
adrenal gland | 100% | 23759.23 | 258 / 258 | 99% | 239.13 | 228 / 230 |
kidney | 100% | 18358.00 | 89 / 89 | 99% | 163.57 | 893 / 901 |
stomach | 100% | 20428.80 | 359 / 359 | 99% | 154.67 | 283 / 286 |
pancreas | 100% | 20140.25 | 328 / 328 | 99% | 195.10 | 176 / 178 |
bladder | 100% | 25588.43 | 21 / 21 | 99% | 166.86 | 498 / 504 |
skin | 100% | 17373.47 | 1805 / 1809 | 95% | 164.97 | 450 / 472 |
liver | 100% | 10103.88 | 226 / 226 | 95% | 106.19 | 386 / 406 |
adipose | 100% | 21360.77 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 28661.13 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 172.51 | 29 / 29 |
muscle | 100% | 36102.32 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 19005.61 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 227.66 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 58.20 | 1 / 1 |
eye | 0% | 0 | 0 / 0 | 99% | 189.19 | 79 / 80 |
heart | 97% | 16452.41 | 831 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 53% | 7762.82 | 488 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1990830 | Biological process | cellular response to leukemia inhibitory factor |
GO_0002183 | Biological process | cytoplasmic translational initiation |
GO_0006446 | Biological process | regulation of translational initiation |
GO_0006413 | Biological process | translational initiation |
GO_1900260 | Biological process | negative regulation of RNA-dependent RNA polymerase activity |
GO_0005829 | Cellular component | cytosol |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0016281 | Cellular component | eukaryotic translation initiation factor 4F complex |
GO_0003743 | Molecular function | translation initiation factor activity |
GO_0004386 | Molecular function | helicase activity |
GO_0005515 | Molecular function | protein binding |
GO_0003724 | Molecular function | RNA helicase activity |
GO_0016887 | Molecular function | ATP hydrolysis activity |
GO_0005524 | Molecular function | ATP binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | EIF4A2 |
Protein name | Eukaryotic translation initiation factor 4A2 Eukaryotic initiation factor 4A-II (eIF-4A-II) (eIF4A-II) (EC 3.6.4.13) (ATP-dependent RNA helicase eIF4A-2) Eukaryotic initiation factor 4A-II (EC 3.6.4.13) (ATP-dependent RNA helicase eIF4A-2) RNA helicase (EC 3.6.4.13) |
Synonyms | hCG_1784041 EIF4F DDX2B |
Description | FUNCTION: ATP-dependent RNA helicase which is a subunit of the eIF4F complex involved in cap recognition and is required for mRNA binding to ribosome. In the current model of translation initiation, eIF4A unwinds RNA secondary structures in the 5'-UTR of mRNAs which is necessary to allow efficient binding of the small ribosomal subunit, and subsequent scanning for the initiator codon. FUNCTION: ATP-dependent RNA helicase which is a subunit of the eIF4F complex involved in cap recognition and is required for mRNA binding to ribosome. In the current model of translation initiation, eIF4A unwinds RNA secondary structures in the 5'-UTR of mRNAs which is necessary to allow efficient binding of the small ribosomal subunit, and subsequent scanning for the initiator codon. . FUNCTION: ATP-dependent RNA helicase which is a subunit of the eIF4F complex involved in cap recognition and is required for mRNA binding to ribosome. In the current model of translation initiation, eIF4A unwinds RNA secondary structures in the 5'-UTR of mRNAs which is necessary to allow efficient binding of the small ribosomal subunit, and subsequent scanning for the initiator codon. . FUNCTION: ATP-dependent RNA helicase which is a subunit of the eIF4F complex involved in cap recognition and is required for mRNA binding to ribosome. In the current model of translation initiation, eIF4A unwinds RNA secondary structures in the 5'-UTR of mRNAs which is necessary to allow efficient binding of the small ribosomal subunit, and subsequent scanning for the initiator codon. . |
Accessions | F8WE11 E7EQG2 ENST00000498746.1 Q14240 ENST00000429589.5 ENST00000323963.10 [Q14240-1] ENST00000443963.5 ENST00000425053.5 ENST00000441007.5 E9PBH4 E7EMV8 J3KSN7 C9JUF0 ENST00000440191.6 [Q14240-2] ENST00000445596.5 ENST00000426808.5 Q9NZE6 |